Aslan Prime Advisory financial advisor in Aptahem's rights issue of SEK 15.6 million
Uppdaterat: för 6 dagar sedan
The Board of Directors of Aptahem AB has today resolved on a rights issue of units amounting to approximately SEK 15.6 million, pursuant to the authorization granted by the Annual General Meeting on March 27, 2026. The proceeds will be used to accelerate the company’s clinical development and discussions with potential partners. Aslan Prime Advisory is acting as financial advisor in connection with the rights issue.
Background and motive Aptahem is a clinical-stage biotechnology company developing aptamer-based therapeutics for life-threatening acute conditions characterized by the interplay of coagulation, inflammation, and tissue damage. The company’s lead candidate, Apta-1, is in early-stage clinical development and has demonstrated promising results in preclinical studies for sepsis and sepsis-related conditions. Currently, the company is working to secure a licensee, partner, or acquirer for Apta-1. The share issue is intended to provide the company with capital to advance Apta-1 toward patient studies, strengthen its financial stability, and drive partnership discussions forward.
The proceeds from the issue shall be used, in order of priority, for:
Clinical development and preparations for patient studies – approximately 50%
Financial stability and ongoing operations – approximately 35%
Partnerships and strategic transactions – approximately 15%
Terms in brief
Each unit consists of three new shares and one warrant of series TO9, issued free of charge.
The subscription price is SEK 1.20 per unit, corresponding to SEK 0.40 per share.
Each existing share entitles the holder to one unit right, and two unit rights entitle the holder to subscribe for one unit.
The record date is September 21, 2026.
The subscription period runs from September 23 to October 7, 2026.
Upon full exercise, the warrants of series TO9 could provide the company with up to approximately SEK 6.5 million in additional capital.
Aslan Prime Advisory is acting as financial advisor in connection with the rights issue.
Read Aptahem’s press release here.
